Group_NN
cash_NN
ow_NN
statement_NOMZ
12_CD
months_NN
to_PIN
12_CD
months_NN
to_PIN
31_CD
Dec_NN
2002_CD
31_CD
Dec_NN
2001_CD
Notes_NN
m_FW
m_FW [BEMA]
Net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
before_IN
exceptional_JJ
items_NN
31_CD
345.5_CD
342.3_CD
Exceptional_JJ
items_NN
12.0_CD
Net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
31_CD
345.5_CD
354.3_CD
Dividend_NN
received_VBN [WZPAST]
from_PIN
joint_JJ
venture_NN
5.4_CD
4.8_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
Interest_NN
paid_VBD
9.2_CD
19.7_CD
Interest_NN
received_VBD
4.9_CD
10.3_CD
Dividends_NN
paid_VBN [WZPAST]
by_PIN
subsidiary_NN
undertakings_GER
to_PIN
minority_NOMZ
interests_NN
1.7_CD
1.7_CD
6.0_CD
11.1_CD
Taxation_NOMZ
57.2_CD
47.6_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
Purchase_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
143.4_CD
91.6_CD
Purchase_NN
of_PIN
intangible_JJ
xed_JJ
assets_NN
4.8_CD
10.2_CD
Sales_NN
of_PIN
tangible_JJ
xed_JJ
assets_NN
1.3_CD
22.1_CD
Purchase_NN
of_PIN
trade_NN
investments_NOMZ
3.4_CD
4.9_CD
Cash_NN
received_VBN [WZPAST]
on_PIN
disposal_NN
of_PIN
investment_NOMZ
in_PIN
Nycomed_NN
Pharma_NN
123.0_CD
Costs_NN
associated_VBN [WZPAST]
with_PIN
disposal_NN
of_PIN
investment_NOMZ
in_PIN
Nycomed_NN
Pharma_NN
3.5_CD
4.9_CD
Sale_NN
of_PIN
trade_NN
investments_NOMZ
1.4_CD
152.4_CD
33.5_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Purchase_NN
of_PIN
45_CD
%_NN
minority_NOMZ
in_PIN
Amersham_NN
Biosciences_NN
24_CD
704.1_CD
Costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
purchase_NN
of_PIN
45_CD
%_NN
minority_NOMZ
in_PIN
Amersham_NN
Biosciences_NN
24_CD
4.5_CD
Other_JJ
acquisitions_NOMZ
40.6_CD
4.9_CD
Other_JJ
disposals_NN
1.0_CD
749.2_CD
3.9_CD
Equity_NOMZ
dividends_NN
paid_VBD
51.6_CD
41.7_CD
Net_JJ
cash_NN
ow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_CC
nancing_VBG
665.5_CD
288.3_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
32,33_CD
74.5_CD
91.4_CD
Financing_GER
Issue_NN
of_PIN
share_NN
capital_NN
25_CD
413.2_CD
16.2_CD
Costs_NN
associated_VBN [WZPAST]
with_PIN
issue_NN
of_PIN
share_NN
capital_NN
5.5_CD
Loans_NN
and_PHC
finance_NN
leases_NN
32,33_CD
161.9_CD
205.3_CD
Repayment_NOMZ
of_PIN
long_JJ
term_NN
loan_NN
32,33_CD
13.6_CD
Capital_NN
contribution_NOMZ
by_PIN
minority_NOMZ
interest_NN
in_PIN
Amersham_NN
Biosciences_NN
8.7_CD
564.7_CD
189.1_CD
Cash_NN
ow_NN
in_PIN
the_DT
year_NN
32,33_CD
26.3_CD
7.8_CD
Analysis_NN
of_PIN
free_JJ
cash_NN
ow_NN
before_IN
exceptional_JJ
items_NN
Free_JJ
cash_NN
ow_NN
from_PIN
:_:
Operating_GER
activities_NOMZ
before_IN
exceptional_JJ
items_NN
31_CD
345.5_CD
342.3_CD
Dividend_NN
received_VBN [WZPAST]
from_PIN
joint_JJ
venture_NN
5.4_CD
4.8_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
6.0_CD
11.1_CD
Taxation_NOMZ
57.2_CD
47.6_CD
Free_NN
cash_NN
ow_NN
after_IN
taxation_NOMZ
and_PHC
returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
287.7_CD
288.4_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
prior_RB
to_PIN
the_DT
disposal_NN
of_PIN
Nycomed_NN
Pharma_NN
148.9_CD
84.6_CD
Free_NN
cash_NN
ow_NN
before_IN
equity_NOMZ
dividends_NN
138.8_CD
203.8_CD
Free_NN
cash_NN
ow_NN
after_IN
equity_NOMZ
dividends_NN
87.2_CD
162.1_CD
Liquid_NN
resources_NN
are_VPRT [PASS]
dened_VBN
as_IN
short_JJ
term_NN
deposits_NN
with_PIN
banks_NN
and_CC
current_JJ
asset_NN
investments_NOMZ
in_PIN
bonds_NN
and_PHC
equities_NOMZ
._.
These_DEMO
total_JJ
22.1_CD
m_NN [BEMA]
2001_CD
96.5_CD
m_NN
and_CC
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
balance_NN
sheet_NN
within_PIN
the_DT
total_NN
of_PIN
short_JJ
term_NN
deposits_NN
and_PHC
investments_NOMZ
._.
54_CD
Amersham_NN
plc_NN
Annual_JJ
Report_NN
&_CC
Accounts_NN
2002_CD
